Last checked at 18 Jan 2022 07:00
18 January 2022
ECO Animal Health Group plc
("ECO" or the "Company") (AIM: EAH)
Chief Executive Officer Appointment
ECO Animal Health Group plc, a leader in the development, registration and marketing of pharmaceutical products for the global animal health market, is pleased to announce that the Board of the Company has approved David Hallas's appointment as Chief Executive Officer and a member of the Board with effect from the 1 April 2022. This follows the announcement on the 26 July 2021 regarding Marc Loomes' intention to retire from ECO during 2022.
David Hallas has over 30 years of experience in the animal health industry and is a qualified veterinarian. He is currently managing director of Sure Petcare, a wholly owned subsidiary of Merck Inc. providing digital based solutions to the companion animal sector with sales of over US$170m. Prior to this role, he was Associate Vice President of MSD Animal Health with full P&L responsibility for mid Europe which comprised a group of 7 European countries with a combined revenue of over US$450m; he has also held senior global, regional and business unit management roles in other animal health businesses within Merck, Schering Plough and Pfizer (now Zoetis) and lived and worked overseas including in the USA. David has substantial experience managing profitable growth through the introduction of new products, including vaccines, and successful merger and acquisition integrations.
Marc Loomes will resign from the Board of ECO on 1 April 2022 and has agreed to support David and the Company in an advisory role for a period of time to ensure a full and thorough handover is effected.
Andrew Jones, Chairman of ECO said:
"We are delighted that David has agreed to join ECO as CEO. He has considerable experience in all our major markets and product areas, and an excellent track record of managing and delivering profitable growth both in large and smaller businesses. We look forward to working with him to build shareholder value in the next exciting phase of ECO's development. The Board also sincerely thanks Marc for his invaluable contribution to the growth and success of ECO over the last 17 years."
Additional Information on the Board Appointment:
The following additional information is provided with regards to the appointment of David Charles Hallas aged 57, in accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules for Companies:
Current directorships/partnerships:
Sureflap Limited
Sureflap LLC
Cambridge Resonant Technologies Ltd.
Directorships/partnerships within the last five years:
None
David Hallas does not currently hold any shares in the Company.
There are no further disclosures required to be made in respect of the appointment under AIM Rule 17 and Schedule 2(g) of the AIM Rules for Companies.
Contacts:
ECO Animal Health Group plc Marc Loomes (CEO) Christopher Wilks (CFO)
| 020 8447 8899
|
IFC Advisory Graham Herring Zach Cohen
| 020 3934 6630
|
Singer Capital Markets (Nominated Adviser & Joint Broker) Mark Taylor George Tzimas
| 020 7496 3000 |
Peel Hunt LLP (Joint Broker) James Steel Dr Christopher Golden
| 020 7418 8900 |
Investec (Joint Broker) Gary Clarence Alex Penney Carlo Spingardi
| 020 7597 5970
|
Equity Developments Hannah Crowe Matt Evans | 020 7065 2692 |
About ECO Animal Health
ECO Animal Health Group plc ("ECO" or "the Group") researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.